About US
Contact us
-
Shorla gains FDA nod for first oral liquid version of Novartis' GleevecIn 2001, a Time Magazine cover storytoutedNovartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “ammunition in the war against cancer.” Along with a picture of the Gleevec pills,2024/12/2
-
Fast-growing Adragos snaps up Swiss CDMO Baccinex, significantly expanding fill-finish firepowerGerman CDMO Adragos Pharma has been on a growth tear this year, drafting plans to boost capacity in Japan, upgrading a facility in France, taking over another from Fresenius Kabi in Norway and more.2024/11/28
-
AZ's Truqap delivers phase 3 win in prostate cancer subtype after recent breast cancer missAfter a recent failed showing in a breast cancer subgroup raised doubts around AstraZeneca’s Truqap, the first-in-class AKT inhibitor is making inroads in a prostate cancer subtype. High-levelresults2024/11/28
-
Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls onBristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. The company has handed pink slips to 195 more employees, according to a New Jersey Worker Adjustment and R2024/11/26
-
Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH studyEight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition. In the phase 3 ZENITH study, Merck’s ac2024/11/26
-
Trump leans toward selecting surgeon and COVID mandate critic Martin Makary for top FDA job: reportsWhile President-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), a crucial sp2024/11/21
-
Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's EnhertuA bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu.2024/11/21
-
Johnson & Johnson, Merck lay off workers in China as local headwinds take a tollJohnson & Johnson and Merck arelaying offworkers in China, according to a story from Bloomberg which cites reports from Chinese news outlets and confirmation from industry sources in the country.2024/11/19
-
Rapid growth spurt for UCB's Bimzelx continues with hidradenitis suppurativa nod marking 5th FDA approvalIt was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in psoriasis after an initial delay. Now with a new nod in hidradenitis suppurativa (2024/11/19
-
With high hopes for the economy, AstraZeneca adds $2B to US investment in manufacturing, R&DCiting a rosy view of the U.S. economy’s potential for growth over the next several years, British Big Pharma AstraZeneca is substantially boosting its investment in manufacturing and R&D in the2024/11/15